Document is current
Any future updates will be listed below
-
Authors
Wang, Xiaoguang
Chen, Canping https://orcid.org/0000-0003-4021-8592
Vuong, Dan
Rodriguez-Rodriguez, Sonia
Lam, Vi
Roleder, Carly
Wang, Jing H. https://orcid.org/0000-0003-4343-2527
Thiruvengadam, Swetha Kambhampati
Berger, Allison
Pennock, Nathan https://orcid.org/0000-0001-5374-7843
Torka, Pallawi
Hernandez-Ilizaliturri, Francisco
Siddiqi, Tanya
Wang, Lili https://orcid.org/0000-0001-5028-2868
Xia, Zheng https://orcid.org/0000-0003-3364-8324
Danilov, Alexey V. https://orcid.org/0000-0003-4461-0970
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA244576)
Leukemia and Lymphoma Society (2319-19)
- License Information
-
More Information
Article History
Received: 3 October 2022
Revised: 22 March 2023
Accepted: 24 March 2023
First Online: 8 April 2023
Competing interests
: AVD has received consulting fees from Abbvie, AstraZeneca, Bayer Oncology, BeiGene, Bristol Meyers Squibb, Genentech, GenMab, Incyte, Janssen, Lilly Oncology, Nurix, Oncovalent, Pharmacyclics and TG Therapeutics and has ongoing research funding from Abbvie, AstraZeneca, Bayer Oncology, Bristol Meyers Squibb, Cyclacel, MEI Pharma, Nurix and Takeda Oncology. PT has received consulting fees from ADC Therapeutics, Genentech and TG Therapeutics.
